Pharmaceutical company KalVista Pharmaceuticals Inc (NASDAQ:KALV) stated on Tuesday its net loss of USD5.9m (USD0.33) per basic and diluted share for the fiscal second quarter ended 31 October 2019.
This marks a decline in earnings when compared to a net loss of USD3.3m (USD0.22 per basic and diluted share) for the same period in 2018.
Revenue of USD3.9m were generated for the three months ended 31 October 2019, down over revenues of USD5.6m for the same period in 2018. Revenue in the three months ended 31 October 2019 consisted of the recognition of a portion of the upfront payment from Merck.
Research and development expenses of USD9.8m were recorded for the three months ended 31 October 2019, an increase versus USD7.9m for the same period in 2018, which reflects the ongoing clinical trial for KVD900 and an increase in expense related to preclinical activities.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation